Pharmaceutical company Boston Therapeutics, Inc. (BTHE-OTC) announced this morning that Benchworks SD, LLC has launched the branding of sugardown® in North America. Boston Therapeutics is a developer of complex carbohydrate therapeutics to manage post meal blood glucose levels, and sugardown® is the company's new natural dietary supplement product that helps people maintain healthy blood sugar levels. Boston Therapeutics states that sugardown® is the first chewable tablet of its kind. It was designed for people who are committed to a balanced diet and exercise to help keep their blood sugar levels healthy.
According to statistics published by the Centers for Disease Control and Prevention, there are 86 million people in the United States who have elevated blood glucose levels. These people may benefit by adding sugardown® to their diet and exercise regimens. According to the International Diabetes Federation, there are 382 million people worldwide living with elevated blood sugar and that number is projected to increase to 592 million by 2035.
Boston Therapeutics' marketing plan for sugardown® is to out-license marketing rights to strategic partners in their jurisdictions of expertise. The company entered into an agreement with Advance Pharmaceutical Co. Ltd. (APC), a Hong Kong-based strategic partner to develop markets for sugardown® in Hong Kong, China, and Macau. This year to date, Boston Therapeutics has sold more than 20,000 bottles of sugardown® to APC to test the Asian market. As part of the plan to increase sales, the company recently entered into a strategic marketing collaboration with Benchworks SD, LLC, a leading branding and marketing agency, aimed at driving brand awareness and growing sales of sugardown® among the large pre-diabetic population in North America.
The main ingredient in sugardown® is made from naturally occurring plant-based mannans (galactomannans) that when combined with a healthy lifestyle and diet have the ability to regulate digestive enzymes, which in turn promotes healthy digestion, optimal sugar absorption, and healthy postprandial glucose levels.
Kristen Kim, a 47-year old woman from San Jose, California, said that what ultimately sold her on the idea of trying sugardown® was the impressive science behind the product, which was formulated by one of the world's leading complex carbohydrate scientists. "I read everything on the sugardown® web site and was impressed that the product was a result of about 30 years of research, development, and testing. I also liked that it was a 'dietary supplement' and not a prescription medication."
Kristen continued, saying, "I usually take two sugardown® tablets before meals, both at home and at restaurants. I always have a full bottle in my tote bag."
David Platt, Ph.D., CEO of Boston Therapeutics, manufacturer of sugardown®, commented, saying, "As an inventor of sugardown®, knowing that we have a natural dietary supplement that can help make a difference in people's lives is very exciting. People who want to maintain a healthy blood sugar level want some options in their life: a little freedom to choose, and that is what sugardown® is all about."
sugardown® is available in a bottle of 60 tablets or a convenient 10-tablet tube. For more information, visit sugardown® on Facebook. To order, visit www.sugardown.com.
Benchworks LLC, based in Chestertown, Maryland, specializes in branding and positioning products by developing marketing promotions, product launches and online solutions for corporate clients ranging from mid-sized firms to Fortune 500 companies. Its client roster includes leading life science companies such as Pfizer Pharmaceuticals, Shire Pharmaceuticals, and Noven Pharmaceuticals, as well as other industry leaders such as Coca-Cola, Chrysler and CB Richard Ellis Inc. Additional information is available at www.benchworks.com.
About Boston Therapeutics, Inc.
Boston Therapeutics, headquartered in Manchester, NH, is an innovator in designing compounds using complex carbohydrate chemistry. The company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases. Additional information is available at www.bostonti.com.